Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy

Gadag, Shivaprasad; Narayan, Reema; Nayak, Yogendra; Garg, Sanjay; Nayak, Usha Yogendra

doi:10.1016/j.ijpharm.2022.122558

Cited by 7 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The experiment was carried out in low vacuum mode at 15 kV. Moisture content and uptake were measured following the protocols described by Gadag et al [60]. The IL-S/O patches were cut into pieces (~1.0 cm 2 ), the weights were measured, and the pieces were placed in a desiccator containing fused calcium chloride for up to 24 h. After 24 h, the patches were collected from the desiccator and re-weighed.…”

Section: Characterization Of the Il-s/o Patchesmentioning

confidence: 99%

Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens

Islam,

Nabila,

Wakabayashi

et al. 2024

Molecules

View full text Add to dashboard Cite

Herein, we report a transdermal patch prepared using an ionic liquid-based solid in oil (IL-S/O) nanodispersion and a pressure-sensitive adhesive (PSA) to deliver the macromolecular antigenic protein, ovalbumin (OVA). The IL-S/O nanodispersion and a PSA were first mixed at an equal weight ratio, then coated onto a release liner, and covered with a support film. To evaluate the effect of the PSA, three types of PSAs, DURO-TAK 87-4098, DURO-TAK 87-4287, and DURO-TAK 87-235A, were used to obtain the corresponding IL-S/O patches SP-4098, SP-4287, and SP-235A, respectively. The prepared IL-S/O patches were characterized for surface morphology, viscoelasticity, and moisture content. In vitro skin penetration and in vivo immunization studies of the IL-S/O patches were performed using Yucatan micropig skin and the C57BL/6NJc1 mice model, respectively. The SP-4098 and SP-4287 delivered 5.49-fold and 5.47-fold higher amounts of drug compared with the aqueous formulation. Although both patches delivered a similar amount of drug, SP-4287 was not detached fully from the release liner after 30 days, indicating low stability. Mice immunized with the OVA-containing SP-4098 produced a 10-fold increase in anti-OVA IgG compared with those treated with an aqueous formulation. These findings suggested that the IL-S/O patch may be a good platform for the transdermal delivery of antigen molecules.

show abstract

Section: Characterization Of the Il-s/o Patchesmentioning

confidence: 99%

Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens

Islam,

Nabila,

Wakabayashi

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…A research study was conducted to obtain the effectiveness of an enhanced RVT patch in a model mouse, where treatment with 7,12-Dimethylbenz(a)anthracene (DMBA) was persuaded chemically into a batch of rat models where one group had orally administered RVT and the rest had RVT patch [16].…”

Section: Cancermentioning

confidence: 99%

A Decade Study on Transdermal Patches on Cancer Redressal: A Review

2023

AJAC

View full text Add to dashboard Cite

The transdermal patches themselves with different modalities and construction represent an excellent alternative for the different standard procedures of cancer treatment therapy (Breast cancer), pre-evaluation of cancer, and mainly other pain relief treatment which are some most researched domains in medical science. The purpose is to present an overview of the literature of 14 years of research and development for transdermal patches for Cancer and Cancer-related complications. Literature researched in a science-direct database for all types of publication search terms were "Transdermal", "Patches", and "Cancer". The development of transdermal patches is taking place from only pain relief measurements alternative to the pre-clinical evaluation including Cancer therapy alternatives.

show abstract

“…Various techniques including nanotechnology [ 11 ], microneedles [ 12 ], and the use of chemical permeation enhancers (CPEs) [ 13 , 14 , 15 ] have been explored to enhance skin permeation for many drugs. CPEs have been adopted extensively due to their benefits including versatility, good safety profile, ease of formulation, cost-effectiveness, and simplified scale-up processes, encouraging their widespread application in topical drug delivery [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches

Kim,

Youssef,

Lee

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

5-fluorouracil (5-FU), commercially available as a topical product, is approved for non-melanoma skin cancer (NMSC) treatment with several clinical limitations. This work aimed to develop 5-FU-loaded topical patches as a potential alternative to overcome such drawbacks. The patches offer accurate dosing, controlled drug release and improved patient compliance. Our study highlights the development of Eudragit® E (EuE)-based drug-in-adhesive (DIA) patches containing a clinically significant high level of 5-FU (approximately 450 µg/cm2) formulated with various chemical permeation enhancers. The patches containing Transcutol® (Patch-TRAN) or oleic acid (Patch-OA) demonstrated significantly higher skin penetration ex vivo than their control counterpart, reaching 5-FU concentrations of 76.39 ± 27.7 µg/cm2 and 82.56 ± 8.2 µg/cm2, respectively. Furthermore, the findings from in vitro permeation studies also validated the superior skin permeation of 5-FU achieved by Patch-OA and Patch-TRAN over 72 h. Moreover, the EuE-based DIA patch platform demonstrated suitable adhesive and mechanical properties with an excellent safety profile evaluated through an inaugural in vivo human study involving 11 healthy volunteers. In conclusion, the DIA patches could be a novel alternative option for NMSC as the patches effectively deliver 5-FU into the dermis layer and receptor compartment ex vivo for an extended period with excellent mechanical and safety profiles.

show abstract

Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy

Cited by 7 publications

References 38 publications

Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens

Ionic Liquid-Based Immunization Patch for the Transdermal Delivery of Antigens

A Decade Study on Transdermal Patches on Cancer Redressal: A Review

Enhanced Skin Permeation of 5-Fluorouracil through Drug-in-Adhesive Topical Patches

Contact Info

Product

Resources

About